Welcome to our dedicated page for ABPRO HLDGS SEC filings (Ticker: ABP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abpro Holdings, Inc. (Nasdaq: ABP) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, including current reports, registration statements, and other disclosures filed with the Securities and Exchange Commission. These filings offer detailed insight into Abpro’s biotechnology business, its antibody therapeutic programs, capital structure, and Nasdaq listing status.
Abpro’s filings include multiple Form 8-K current reports describing material events such as reverse stock split approval and implementation, Nasdaq listing notices and hearing outcomes, submission and clearance of an Investigational New Drug (IND) application for ABP-102 / CT-P72, and scientific data presentations in collaboration with Celltrion. These documents help investors understand how Abpro is addressing listing requirements, advancing its lead HER2 × CD3 T-cell engager into Phase 1 trials, and communicating key operational changes.
The company has also filed registration statements, including a Form S-1 related to a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. That prospectus explains how Abpro may direct YA to purchase shares of common stock, outlines potential resale of those shares, and discusses associated risks. Together with other filings, it sheds light on Abpro’s financing arrangements and its status as an emerging growth and smaller reporting company.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the core points of lengthy documents such as registration statements and complex 8-Ks. Users can quickly see what each filing covers—whether it relates to clinical development of ABP-102 / CT-P72, changes in capital structure, or Nasdaq compliance—while retaining the ability to review the full text from EDGAR. The filings page also surfaces information about Abpro’s listed securities, including common stock (ABP) and warrants (ABPWW), and captures ongoing updates as new reports are filed.
Abpro Holdings, Inc. reported that Nasdaq’s Hearings Panel has decided to delist its common stock and public warrants because the company did not meet the minimum equity requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026. Trading on Nasdaq is scheduled to be suspended at the open on February 23, 2026.
The company has 15 days from February 18, 2026 to request a review by the Nasdaq Listing and Hearing Review Council and expects to appeal. If no appeal is pursued or successful, Nasdaq is expected to file a Form 25 to delist and deregister the securities under Section 12(b).
After Nasdaq trading is suspended, Abpro expects its common stock and public warrants to be eligible for quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW.” The company warns investors that OTC Pink trading may involve reduced information, lower liquidity, and greater price volatility, and it cannot assure that any broker-dealer will make a market in its securities.
Abpro Holdings, Inc. reported that Nasdaq has notified the company it is no longer in compliance with several board and committee independence listing rules following the recent resignations of two independent directors, creating additional bases for potential delisting from The Nasdaq Capital Market.
Nasdaq cited noncompliance with rules requiring a majority-independent board, a three-member independent audit committee, and a two-member independent compensation committee. Abpro must present its views to a Nasdaq Hearings Panel by February 12, 2026, and has a cure period for the compensation committee extending to certain future shareholder meeting dates.
On February 9, 2026, Abpro appointed M. Fatih Karatas and Mary Gunn as Class II directors and to the audit, compensation, and nominating and corporate governance committees, aiming to address the independence and composition deficiencies. The company notes there is no immediate impact on the listing of its common stock or warrants, but there is no assurance it will regain full compliance or that the Panel will grant continued listing.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have disclosed a passive ownership stake in Abpro Holdings Inc. They report beneficial ownership of 196,537 shares of Abpro common stock, representing 6.8% of the outstanding class, as of the event date of 12/31/2025.
All 196,537 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive authority. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Abpro.
Abpro Holdings, Inc. reported that two members of its Board of Directors, Anthony D. Eisenberg and Sooyoung Lee, have resigned from the board and all related committees. Both resignations were effective in late January 2026 and were explicitly stated as not arising from any disagreement with the company, its board, or its management on operations, policies, or practices.
Following these departures, the Board has begun a process to identify and appoint new qualified independent directors to fill the vacancies and to meet applicable Nasdaq Stock Market requirements within the time periods allowed by the Nasdaq Listing Rules.
Abpro Holdings, Inc. entered into an unsecured $147,000 loan agreement with its Chief Executive Officer and Chairman, Miles J.W. Suk, to pay the premium for its directors’ and officers’ liability insurance. The CEO will pay the insurer or broker directly, and the funds may be used only for that insurance cost.
The loan runs for nine months and can be repaid early without penalty. No interest is charged for the first three months after funding; after that, the outstanding principal bears interest at a variable rate equal to three-month Term SOFR plus 2.0% per year, with interest due at maturity or earlier repayment. The loan is unsecured and not guaranteed by any third party.
On January 16, 2026, director Ian McDonald resigned from Abpro’s board and all board committees, with the company stating his resignation was not due to any disagreement over operations, policies, or practices. The board appointed Dr. Byung-Hak Yoon as a Class I director to fill the vacancy, with a term ending at the 2028 annual meeting, and named him to the Audit, Compensation, and Nominating and Corporate Governance Committees. Dr. Yoon, age 51, brings extensive leadership experience in biotechnology and medical companies and will receive the company’s standard compensation for independent directors.
Abpro Holdings, Inc. reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, its lead multispecific antibody oncology program. The therapy is being co-developed with Celltrion, Inc., and this clearance allows clinical studies of the candidate to begin under the IND. The update was shared via a press release furnished under a Regulation FD disclosure.
Abpro Holdings, Inc. disclosed that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to initiate a phase 1 clinical trial of its T cell engager candidate ABP-102/CT-P72 for HER2-positive cancers. This marks a step toward first-in-human testing of the therapy, subject to regulatory review.
The update comes via a current report that references a company press release containing further details and includes the release as an exhibit. The company notes that this information is being furnished rather than filed under securities laws, which limits how it is incorporated into other regulatory documents.
Abpro Holdings, Inc. has filed a prospectus supplement that incorporates its Form 10-Q for the quarter ended September 30, 2025. The company reported a net loss of $1.7 million for the quarter and $8.5 million for the nine months, driven mainly by research and development and general and administrative expenses. Cash was only $328 thousand as of September 30, 2025, compared with current liabilities of $17.3 million, resulting in a stockholders’ deficit of $15.6 million. Management concluded there is substantial doubt about Abpro’s ability to continue as a going concern and plans to seek additional equity or debt financing and collaborations. The company implemented a 1-for-30 reverse stock split effective October 31, 2025 and remains under a Nasdaq panel exception through March 30, 2026 after prior noncompliance with minimum bid price, market value of publicly held shares and market value of listed securities requirements.
Abpro Holdings, Inc. filed a Form S-1 for the offer and resale of up to 9,775,017 registered shares of Common Stock issuable under its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. YA may resell these shares from time to time.
The company will not receive proceeds from YA’s resales. Abpro may receive up to $50,000,000 in aggregate gross proceeds from sales of Common Stock to YA under the SEPA, at Abpro’s discretion and subject to SEPA terms.
The filing notes potential market impact from these sales. As context, the shares registered represent approximately 361% of Common Stock outstanding as of November 6, 2025, when 2,705,061 shares were outstanding. The offering table indicates 12,480,078 shares outstanding after the offering. Abpro effected a 1-for-30 reverse stock split on October 31, 2025. The Common Stock and Public Warrants trade on Nasdaq as “ABP” and “ABPWW”.